

Quarterly Report

Q4/2019

FINANCIAL YEAR 2019 SUCCESSFULLY COMPLETED

- + Guidance for group revenues and EBITDA achieved: 746 MEUR revenue (guidance: 720 - 750 MEUR), 178 MEUR EBITDA (adjusted guidance: 175 - 190 MEUR)
- + Group revenues 4% up year-on-year
 - + Organic revenues on prior year level, excluding Telematics Infrastructure revenue growth of 7%
 - + 11% increase in recurring revenues
 - + recurring revenues at 62% of total revenues (PY: 58%)
- + EBITDA 5% below prior year, on a pro forma basis 5% above prior year at 198 MEUR
- + Earnings per share at 1.49 EUR (PY: 1.92 EUR), pro forma at 1.87 EUR (PY: 1.85 EUR)
- + Cash net income per share of 2.12 EUR (PY: 2.52 EUR), on pro forma basis 2.51 EUR (PY: 2.45 EUR)
- + Net debt increase to 402.8 MEUR (31.12.2018: 283.1 MEUR) due to acquisitions, one-off expenses (M&A costs, settlement of stock options) and increased share buyback volume

Q4/19 FINANCIALS

- + Group revenues of 206 MEUR, 6% above the prior year quarter
 - + Organic revenue development on prior year level, excluding TI revenue growth of 8%
 - + 10% increase in recurring revenues
- + EBITDA of 51.9 MEUR, 6% below prior year, mainly due to lower TI non-recurring earnings

KEY FIGURES

| EUR '000 | 01.10.- 31.12.2019 | 01.10.- 31.12.2018 (adjusted) | Change | 01.01.- 31.12.2019 | 01.01.- 31.12.2018 (adjusted) | Change |
|-------------------------------------|-----------------------|-------------------------------------|--------|-----------------------|-------------------------------------|--------|
| Revenue | 206,099 | 194,777 | 6% | 745,822 | 717,023 | 4% |
| EBITDA | 51,902 | 55,025 | -6% | 178,020 | 187,836 | -5% |
| <i>Margin</i> | 25% | 28% | | 24% | 26% | |
| EPS (EUR) - diluted** | 0.43 | 0.67 | | 1.49 | 1.92 | |
| Cash net income (EUR)* ** | 30,592 | 43,273 | | 103,412 | 124,811 | |
| Cash net income per share (EUR)* ** | 0.63 | 0.87 | -28% | 2.12 | 2.52 | -16% |
| Number of shares outstanding ('000) | 48,413 | 49,206 | | 48,413 | 49,206 | |
| Net debt | 402,824 | 283,122 | | 402,824 | 283,122 | |

* Cash net income: Net income before minority interest plus amortization of intangible assets except amortization on in-house capitalized software.

** Based on preliminary tax calculations

NOTICES

The figures and information contained in this preliminary financial report are preliminary and unaudited and are subject to audit and approval by the Supervisory Board. The final and audited results for the fourth quarter of 2019 and the Annual Report 2019 will be published on 25 March 2020.

Unless otherwise stated, all information and explanations in this report relate to the fourth quarter of 2019 and 2018 (adjusted), i.e. the three-month period October 1 to December 31 (Q4) and all percentage changes relate to the respective prior-year comparison.

CGM applies the new accounting standard IFRS 16 for the first time in the 2019 financial year, which means that all leases that fall within the scope of IFRS 16 must be recognised as finance leases (right-of-use asset).

BUSINESS DEVELOPMENT Q4/2019 - SIGNIFICANT EVENTS

In September, the Management Board resolved to repurchase up to 930,825 shares, corresponding to approximately 1.75% of the current share capital and limited to such a number of shares that representing a total volume of 48.4 MEUR (excluding transaction costs). The repurchase started on September 18, 2019 and was terminated on October 31, 2019 by further resolution of the Management Board. A total of 415,559 treasury shares with a total volume of 22.9 MEUR were purchased during the period from September 18 to October 30, 2019, of which 282,496 shares were acquired in Q4/19 with a volume of 15.7 MEUR. At the end of October, treasury shares accounted for 9.03% of total capital.

In November, CGM became the first manufacturer to receive approval from gematik for the eHealth connector Kocobox Med+. The new software upgrade will enable the medical applications NFDm (Emergency Data Management), eMP (Electronic Medication Plan) and perspectivevely KOM-LE (Electronic Letters) - representing new applications that use QES (Qualified Electronic Signature), among others. To cover the acquisition and operating costs for the eHealth connector and the new medical eHealth services, financing mechanisms have already been agreed between the statutory health insurance funds and doctors or dentists. Approval was granted subject to field tests for the applications.

In December, CGM acquired 100% of EPSILOG SAS, a leading provider of healthcare IT with a focus on physiotherapists and ambulatory care in France. EPSILOG achieved revenues of more than 14 MEUR in the 2018 fiscal year with 44,000 customers. EPSILOG will be consolidated in the AIS segment.

EARNINGS DEVELOPMENT GROUP

| EUR '000 | 01.10.- 31.12.2019 | 01.10.- 31.12.2018 (adjusted) | Change | 01.01.- 31.12.2019 | 01.01.- 31.12.2018 (adjusted) | Change |
|-------------------------------|-----------------------|-------------------------------------|--------|-----------------------|-------------------------------------|--------|
| Sales to third parties | 206.1 | 194.8 | 6% | 745.8 | 717.0 | 4% |
| thereof company acquisitions | 11.7 | 2.3 | | 34.5 | 6.8 | |
| proportion of recurring sales | 58% | 56% | | 62% | 58% | |
| EBITDA | 51.9 | 55.0 | -6% | 178.0 | 187.8 | -5% |
| in % of sales | 25% | 28% | | 24% | 26% | |

Revenues for the full year 2019 increased by 28.8 MEUR (+4%) to 745.8 MEUR. Acquisitions contributed with 34.5 MEUR (PY: 6.8 MEUR) to revenues. On an organic basis, revenues were on a prior year level (- 0.4% yoy). Outside of Telematics Infrastructure, organic growth for the full year amounted to 7%. In the fourth quarter, revenues increased by 11.3 MEUR (+6%) to 206 MEUR. Acquisitions contributed with 11,7 MEUR (PY: 2.3 MEUR) to revenues. Organic growth in the fourth quarter of 2019 amounted to 0.1% year-on-year. Outside of Telematics Infrastructure, organic growth showed a 8% increase.

Recurring revenues increased by 11% to 460.8 MEUR in 2019 and by 10% in the fourth quarter to 119.5 MEUR, mainly due to higher contributions from recurring revenues in the TI segment and increased maintenance volumes in the HIS and AIS segments.

Consolidated Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) for the full year 2019 amounted to 178.0 MEUR (PY: 187.8 MEUR on an adjusted basis). The EBITDA margin amounted to 24% compared to 26% (adjusted) in 2018. EBITDA included effects of 17.3 MEUR from the first-time application of IFRS 16 (thereof 6.7 MEUR in the AIS segment, 2.0 MEUR in the PCS segment, 2.8 MEUR in the HIS segment, and 0.7 MEUR in the CHS segment). Pro forma Group EBITDA amounted to 198 MEUR with a pro forma EBITDA margin of 26.5% and was adjusted for M&A-related costs of 16.1 MEUR (thereof 13.1 MEUR already reported in Q3 report) and 3.9 MEUR in connection with the revaluation of the stock option of a former member of the Executive Board, which was accounted for as "cash settled". EBITDA for the fourth quarter was 51.9 MEUR (PY: 55.0 MEUR on an adjusted basis), where IFRS 16 contributed positively with 4.8 MEUR (thereof 1.6 MEUR in the AIS segment, 0.5 MEUR in the PCS segment, 0.7 MEUR in the HIS segment, and 0.2 MEUR in the CHS segment). The corresponding operating margin was 25%, compared to 28% (adjusted) in 2018.

In fiscal year 2019, capitalized in-house services amounted to 24.6 MEUR (PY: 18.5 MEUR). The corresponding amortization of capitalized in-house services amounted to 4.3 MEUR in 2019 (PY: 4.7 MEUR). For Q4 2019 the capitalized in-house services expenses 7.6 MEUR (PY: 5.0 MEUR) with amortization of 0.9 MEUR (PY: 1.3 MEUR).

Based on a preliminary tax calculation, net income for the full year 2019 amounted to 74.0 MEUR, compared to 96.3 MEUR (adjusted) in the reference period of last year. Expected earnings per share (diluted) amounted to 1.49 EUR, compared to EUR 1.92 in the prior year reference period, on a pro forma basis 1.87 EUR. Net income for the fourth quarter was 21.3 MEUR, compared to 34.1 MEUR (adjusted) in the reference period of last year. Expected earnings per share (diluted) amounted to 0.43 EUR, compared to 0.67 EUR in the prior year period, on a pro forma basis 0.49 EUR.

The expected cash net income decreased from 124.8 MEUR for the full year 2018 (adjusted) to 103.4 MEUR for the reporting period 2019. This corresponds to a preliminary cash net income per share of 2.12 EUR for the full year 2019 (PY: 2.52 EUR on an adjusted basis). Preliminary cash net income per share on a pro forma basis amounted to 2.51 EUR. In the fourth quarter, the expected cash net income decreased from 43.3 MEUR in the prior year (adjusted) to 30.6 MEUR. This corresponds to a preliminary cash net income per share of 0.63 EUR for the fourth quarter of 2019 (PY: 0.87 EUR on an adjusted basis), on a pro forma basis 0.69 EUR per share.

EARNINGS DEVELOPMENT OF THE BUSINESS SEGMENTS

Ambulatory Information Systems (AIS)

| EUR '000 | 01.10.- 31.12.2019 | 01.10.- 31.12.2018 | Change | 01.01.- 31.12.2019 | 01.01.- 31.12.2018 | Change |
|-------------------------------|-----------------------|-----------------------|--------|-----------------------|-----------------------|--------|
| Sales to third parties | 118.2 | 118.8 | 0% | 461.4 | 461.9 | 0% |
| thereof company acquisitions | 10.5 | 1.6 | | 30.7 | 4.6 | |
| proportion of recurring sales | 69% | 62% | | 69% | 60% | |
| EBITDA | 42.2 | 41.2 | 3% | 158.0 | 158.7 | 0% |
| in % of sales | 35.7% | 34.7% | | 34.2% | 34.4% | |

- + The software business with physicians, dentists, and medical laboratories achieved revenues of 461.4 MEUR in 2019, slightly above the previous year's level and within the adjusted guidance. In the fourth quarter, revenues amounted to 118.2 MEUR, thereby roughly on the prior year level.
- + Acquisitions, including GIS and Qualizorg among others, contributed 30.7 MEUR to revenues for the full year (PY: 4.6 MEUR) and 10.5 MEUR for the fourth quarter (PY: 1.6 MEUR).
- + Due to the strong prior year revenues in the Telematics Infrastructure 2019, the organic revenue development is down by 7% for the full year and by 9% in the fourth quarter year-on-year. Excluding Telematics Infrastructure, organic revenue growth amounts to 5% for 2019 and 4% for the fourth quarter of 2019. The increase in the fourth quarter is mainly due to a good development in the German and Dutch software business as well as the due to a strong laboratory business in the USA.
- + Recurring revenues increased by 14% to 317 MEUR in 2019 and by 11% to 81.2 MEUR in the fourth quarter, mainly due to growth in TI services.

Pharmacy Information Systems (PCS)

| EUR '000 | 01.10.- 31.12.2019 | 01.10.- 31.12.2018 | Change | 01.01.- 31.12.2019 | 01.01.- 31.12.2018 | Change |
|-------------------------------|-----------------------|-----------------------|--------|-----------------------|-----------------------|--------|
| Sales to third parties | 36.4 | 34.4 | 6% | 119.8 | 113.4 | 6% |
| thereof company acquisitions | 0.3 | 0.1 | | 0.7 | 0.5 | |
| proportion of recurring sales | 52% | 51% | | 60% | 61% | |
| EBITDA | 10.3 | 12.3 | -17% | 35.9 | 33.5 | 7% |
| in % of sales | 28.2% | 35.9% | | 29.9% | 29.6% | |

- + In the fourth quarter of 2019, the pharmacy software business continued its good growth in the course of business in 2019. Revenues increased by 6% to 36.4 MEUR compared to last year, and for the full year also by 6% to 119.8 MEUR. Acquisitions contributed only marginally to revenue growth.
- + Organic growth amounted to 5% for both the full year and the fourth quarter of 2019. Growth in the fourth quarter was mainly due to the replacement of Windows 7 and the sale of hardware such as routers in Italy.
- + Recurring revenues increased by 5% to 72 MEUR in 2019 and by 7% to 19 MEUR in the fourth quarter of 2019.

Hospital Information Systems (HIS)

| EUR `000 | 01.10.- 31.12.2019 | 01.10.- 31.12.2018 | Change | 01.01.- 31.12.2019 | 01.01.- 31.12.2018 | Change |
|-------------------------------|-----------------------|-----------------------|--------|-----------------------|-----------------------|--------|
| Sales to third parties | 36.0 | 29.8 | 21% | 116.3 | 101.3 | 15% |
| thereof company acquisitions | 0.2 | 0.4 | | 1.3 | 0.6 | |
| proportion of recurring sales | 47% | 54% | | 57% | 60% | |
| EBITDA | 7.4 | 5.9 | 25% | 14.7 | 11.6 | 26% |
| in % of sales | 20.4% | 19.9% | | 12.6% | 11.5% | |

+ Revenues growth in hospital information systems amounted to 15% in 2019 and 21% in the fourth quarter with only minor consolidation effects.

+ The organic revenue growth of 16% in 2019 and 21% in the fourth quarter is mainly driven by the major order from Niederösterreichische Landeskliniken-Holding (NÖLKH) which was received in the second quarter. Over the next 6 years, NÖLKH and CGM are planning the rollout of a company-wide, harmonized information system in medicine and care in the total of 19 hospitals with more than 7,600 beds at 27 locations under the project name "NÖKIS".

+ Recurring revenues increased by 8% to 65.9 MEUR in 2019 and by 8% to 17.1 MEUR in the fourth quarter

Consumer & Health Management Information Systems (CHS)

| EUR `000 | 01.10.- 31.12.2019 | 01.10.- 31.12.2018 | Change | 01.01.- 31.12.2019 | 01.01.- 31.12.2018 | Change |
|-------------------------------|-----------------------|-----------------------|--------|-----------------------|-----------------------|--------|
| Sales to third parties | 15.4 | 11.9 | 30% | 48.2 | 40.4 | 19% |
| thereof company acquisitions | 0.7 | 0.2 | | 1.9 | 1.1 | |
| proportion of recurring sales | 14% | 16% | | 12% | 13% | |
| EBITDA | 5.9 | 4.5 | 32% | 16.8 | 13.5 | 25% |
| in % of sales | 38.0% | 37.5% | | 34.7% | 33.3% | |

+ Revenues in the CHS segment increased by 19% for the full year and by 30% in the fourth quarter.

+ Organic growth was 18% for 2019 and 29% in the fourth quarter. The growth in the fourth quarter resulted primarily from a good order situation with pharmaceutical companies and newly concluded contracts with health insurance companies in the area of family doctor-based care.

+ Recurring revenues increased by 9% to 5.8 MEUR in 2019 and by 15% to 2.2 MEUR in the fourth quarter.

+ Acquisitions contributed to revenue growth with 1.9 MEUR in 2019 and with 0.7 MEUR in fourth quarter.

Other business activities and consolidation

| EUR `000 | 01.10.- 31.12.2019 | 01.10.- 31.12.2018 (adjusted) | Change | 01.01.- 31.12.2019 | 01.01.- 31.12.2018 (adjusted) | Change |
|------------------------|-----------------------|-------------------------------------|--------|-----------------------|-------------------------------------|--------|
| Sales to third parties | 0.1 | 0.0 | | 0.1 | 0.1 | |
| EBITDA | -13.8 | -8.8 | | -47.3 | -29.4 | |

+ Other business activities and consolidation include central functions and central software development.

+ In the fourth quarter of 2019, EBITDA declined by 5.0 MEUR to -13.8 MEUR, due to expanded software development activities and further M&A costs.

Group

Revenue in the range of 765 MEUR to 815 MEUR are expected for 2020, which corresponds to an organic growth rate of 0 to 6 percent.

The adjusted EBITDA is expected to be in the range of 195 MEUR to EUR 215 MEUR .

The adjusted earnings per share are expected in the range of 1.70 EUR and 1.95 EUR.

Segments

The following development is expected for the reporting segments in the new structure introduced in the fourth quarter of 2019 for the 2020 financial year (see appendix):

- + AIS revenues are expected in a range between 453 MEUR and 485 MEUR. This includes approximately 15 MEUR from the acquisition of Epsilog in France. Revenues for the TI business will be below the high level of 2019.
- + The PCS segment is expected to generate revenues of 124 MEUR to 134 MEUR. Revenues for the TI rollout are expected to be in the low double-digit million range.
- + The HIS segment is expected to achieve revenues in the range of 142 MEUR to 148 MEUR, including a low single-digit million Euro amount from the acquisition of H&S Qualita and the TI rollout.
- + The new CHS segment is expected to achieve revenues of between 46 MEUR and 48 MEUR in 2020.

The above guidance for the current fiscal year was prepared in January 2020 and does not take into account the effects of currently uncompleted acquisitions and potential transactions during fiscal year 2020. The guidance for 2020 represents the management's best estimate of future market conditions and the development of CompuGroup Medical's business segments in this environment and may be influenced in particular by delays in the implementation of the Telematics Infrastructure for which the company is not responsible.

CompuGroup Medical SE will report adjusted key figures for operating income (EBITDA) and earnings per share from fiscal year 2020 onwards. These key figures are not defined under the International Financial Reporting Standards (IFRS) and should be regarded as supplementary information. The adjusted EBITDA and adjusted earnings per share do not include effects from the acquisition and disposal of subsidiaries, business units and investments (including effects from the subsequent measurement of contingent purchase price liabilities), depreciation, amortization and write-ups on investments, effects from the acquisition, construction and disposal of real estate, impairment losses and write-ups on owner-occupied real estate, expenses in connection with share-based compensation programs for management, taxes attributable to the above effects and other non-operating or non-periodic one-off effects.

Preliminary Consolidated Income Statement

for the reporting period of January 1 - December 31, 2019

| EUR '000 | 01.10.- 31.12.2019 | 01.10.- 31.12.2018 (adjusted) | 01.10.- 31.12.2018 | 01.01.- 31.12.2019 | 01.01.- 31.12.2018 (adjusted) | 01.01.- 31.12.2018 |
|-------------------------------------------------------------------------|-----------------------|-------------------------------------|-----------------------|-----------------------|-------------------------------------|-----------------------|
| Sales revenues | 206,099 | 194,777 | 194,777 | 745,822 | 717,023 | 717,023 |
| Capitalized in-house services | 7,626 | 5,004 | 5,004 | 24,570 | 18,512 | 18,512 |
| Other income | 4,810 | 4,348 | 4,348 | 13,198 | 8,034 | 8,034 |
| Expenses for goods and services purchased | -42,751 | -40,703 | -40,704 | -138,956 | -151,428 | -151,428 |
| Personnel costs | -89,090 | -71,863 | -75,357 | -339,488 | -281,413 | -286,767 |
| Net impairment losses on financial and contract assets | -1,687 | -1,088 | -1,088 | -4,096 | -2,562 | -2,562 |
| Other expenses | -33,105 | -35,449 | -35,449 | -123,030 | -120,330 | -120,330 |
| Earnings before interest, taxes, depr. and amortization (EBITDA) | 51,902 | 55,025 | 51,532 | 178,020 | 187,836 | 182,482 |
| Depreciation of property, plant and equipment | -7,985 | -3,051 | -3,051 | -28,801 | -11,415 | -11,415 |
| Earnings before interest, taxes and amortization (EBITA) | 43,917 | 51,974 | 48,480 | 149,220 | 176,421 | 171,067 |
| Amortization of intangible assets | -10,230 | -10,455 | -10,455 | -33,658 | -33,188 | -33,188 |
| Earnings before interest and taxes (EBIT) | 33,687 | 41,519 | 38,025 | 115,562 | 143,233 | 137,879 |
| Result from associates recognized at equity | 587 | -65 | -65 | -1,707 | -293 | -293 |
| Financial income | 387 | 654 | 654 | 2,074 | 2,010 | 2,010 |
| Financial expenses | -2,617 | -578 | -578 | -7,113 | -10,845 | -10,845 |
| Earnings before taxes (EBT) | 32,043 | 41,530 | 38,036 | 108,815 | 134,105 | 128,751 |
| Income taxes for the period* | -10,769 | -7,396 | -6,346 | -34,785 | -37,763 | -36,156 |
| Results from continued operations | 21,274 | 34,134 | 31,689 | 74,030 | 96,342 | 92,595 |
| Profit for the period from discontinued operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Consolidated net income of the period | 21,274 | 34,134 | 31,689 | 74,030 | 96,342 | 92,595 |
| of which: allocated to the parent company | 21,249 | 34,158 | 31,713 | 73,682 | 96,085 | 92,338 |
| of which: allocated to non-controlling interests | 25 | -24 | -24 | 347 | 257 | 257 |
| Earnings per share (for profit from continuing operations) | | | | | | |
| undiluted (EUR) | 0.44 | 0.69 | 0.64 | 1.51 | 1.94 | 1.86 |
| diluted (EUR) | 0.43 | 0.67 | 0.63 | 1.49 | 1.92 | 1.85 |

* Preliminary tax calculation

Preliminary Statement of Financial Position

as at 31 December 2019

ASSETS*

| EUR `000 | 31.12.2019 | 31.12.2018 (adjusted) | 31.12.2018 |
|--------------------------------------------|------------------|--------------------------|----------------|
| Non-current assets | | | |
| Intangible assets | 660,778 | 536,540 | 536,540 |
| Property, plant and equipment | 87,817 | 83,653 | 83,653 |
| Use rights | 40,470 | 0 | 0 |
| Interests in affiliates (valued at-equity) | 927 | 9,716 | 9,716 |
| Other investments | 1,491 | 725 | 725 |
| Finance Lease trade receivables | 14,826 | 11,984 | 11,984 |
| Contract assets | 56 | 1,598 | 1,598 |
| Other financial assets | 8,589 | 1,606 | 1,606 |
| Other non-financial assets | 1,200 | 1,200 | 1,200 |
| Deferred tax asset | 9,559 | 8,476 | 8,476 |
| | 825,713 | 655,498 | 655,498 |
| Current assets | | | |
| Inventories | 27,576 | 19,579 | 19,579 |
| Trade account receivables | 102,445 | 105,596 | 105,596 |
| Receivables from finance leases | 7,783 | 5,802 | 5,802 |
| Contract assets | 13,784 | 8,409 | 8,409 |
| Other financial assets | 3,146 | 2,623 | 2,623 |
| Other non-financial assets | 17,108 | 15,588 | 15,588 |
| Income tax receivables | 5,754 | 8,854 | 8,854 |
| Cash & cash equivalents | 46,521 | 25,302 | 25,302 |
| | 224,118 | 191,754 | 191,754 |
| Assets qualified as held for sale | 0 | 1,059 | 1,059 |
| | 1,049,831 | 848,311 | 848,311 |

* The preliminary unaudited figures are based on a preliminary tax calculation and initial consolidation of companies acquired at the end of 2019, which may be subject to adjustments until the audited figures are available.

SHAREHOLDER EQUITY AND LIABILITIES*

| EUR `000 | 31.12.2019 | 31.12.2018 (adjusted) | 31.12.2018 |
|---------------------------------------------------------------------------------|------------------|--------------------------|----------------|
| Equity | | | |
| Subscribed capital | 53,219 | 53,219 | 53,219 |
| Treasury shares | -86,322 | -45,259 | -45,259 |
| Reserves | 301,007 | 253,757 | 262,928 |
| Capital and reserves allocated to the shareholders of the parent company | 267,904 | 261,717 | 270,888 |
| Non-controlling interests | 804 | 2,111 | 2,111 |
| | 268,708 | 263,828 | 272,999 |
| Non-current liabilities | | | |
| Provisions for post-employment benefits and other non-current provisions | 30,998 | 24,785 | 24,785 |
| Liabilities to banks | 415,314 | 302,602 | 302,602 |
| Contract liabilities | 6,114 | 7,108 | 7,108 |
| Purchase price liabilities | 7,791 | 3,789 | 3,789 |
| Lease Liabilities | 26,091 | 0 | 0 |
| Other financial liabilities | 13,619 | 17,135 | 17,135 |
| Other non-financial liabilities | 2,202 | 1,263 | 1,263 |
| Deferred tax liabilities | 61,244 | 43,510 | 43,510 |
| | 563,374 | 400,192 | 400,192 |
| Current liabilities | | | |
| Liabilities to banks | 34,031 | 5,822 | 5,822 |
| Contract liabilities | 40,361 | 33,951 | 33,951 |
| Purchase price liabilities | 9,663 | 9,486 | 9,486 |
| Trade payables | 46,398 | 39,293 | 39,293 |
| Income tax liabilities | 7,782 | 14,820 | 18,750 |
| Other provisions | 40,808 | 50,801 | 37,700 |
| Lease Liabilities | 14,333 | 0 | 0 |
| Other financial liabilities | 12,216 | 11,592 | 11,592 |
| Other non-financial liabilities | 12,157 | 18,286 | 18,286 |
| | 217,749 | 184,051 | 174,880 |
| Liabilities related to assets held for sale | 0 | 240 | 240 |
| | 1,049,831 | 848,311 | 848,311 |

* The preliminary unaudited figures are based on a preliminary tax calculation and initial consolidation of companies acquired at the end of 2019, which may be subject to adjustments until the audited figures are available.

Appendix

EARNINGS DEVELOPMENT ACCORDING TO NEW SEGMENT STRUCTURE

CompuGroup Medical SE changed its segment reporting in the 2019 financial year.

The previous reporting segment Health Connectivity Services (HCS) was transferred to the future reporting segment Consumer and Health Management Information Systems (CHS). The medication data business was integrated into the Ambulatory Information Systems (AIS) reporting segment. In addition, product development activities that were previously reported under other business activities were allocated to the new CHS segment.

Furthermore, the laboratory information systems business was reclassified from the Ambulatory Information Systems (AIS) reporting segment to the Hospital Information Systems (HIS) reporting segment.

In addition, changes and realignment of individual Group reporting units (profit centers) led to further changes in the composition of the business and reporting segments, which in particular affected the reporting segments Ambulatory Information Systems (AIS) and Pharmacy Communication Systems (PCS).

Ambulatory Information Systems (AIS)

| EUR `000 | 01.10.- 31.12.2019 | 01.10.- 31.12.2018 (adjusted) | Change | 01.01.- 31.12.2019 | 01.01.- 31.12.2018 (adjusted) | Change |
|------------------------------|-----------------------|-------------------------------------|--------|-----------------------|-------------------------------------|--------|
| Sales to third parties | 113.9 | 116.1 | -2% | 444.6 | 448.1 | -1% |
| thereof company acquisitions | 10.5 | 1.6 | | 30.7 | 4.6 | |
| EBITDA | 42.6 | 41.0 | 4% | 160.4 | 162.5 | -1% |
| in % of sales | 37.4% | 35.3% | | 36.1% | 36.3% | |

Pharmacy Information Systems (PCS)

| EUR `000 | 01.10.- 31.12.2019 | 01.10.- 31.12.2018 (adjusted) | Change | 01.01.- 31.12.2019 | 01.01.- 31.12.2018 (adjusted) | Change |
|------------------------------|-----------------------|-------------------------------------|--------|-----------------------|-------------------------------------|--------|
| Sales to third parties | 36.1 | 33.3 | 8% | 119.4 | 110.9 | 8% |
| thereof company acquisitions | 0.3 | 0.1 | | 0.7 | 0.5 | |
| EBITDA | 11.0 | 11.7 | -7% | 31.9 | 28.9 | 10% |
| in % of sales | 30.4% | 35.2% | | 26.7% | 26.1% | |

Hospital Information Systems (HIS)

| EUR `000 | 01.10.- 31.12.2019 | 01.10.- 31.12.2018 (adjusted) | Change | 01.01.- 31.12.2019 | 01.01.- 31.12.2018 (adjusted) | Change |
|------------------------------|-----------------------|-------------------------------------|--------|-----------------------|-------------------------------------|--------|
| Sales to third parties | 41.4 | 34.9 | 19% | 135.9 | 119.9 | 13% |
| thereof company acquisitions | 0.2 | 0.4 | | 1.3 | 0.6 | |
| EBITDA | 8.8 | 7.3 | 20% | 19.3 | 14.1 | 37% |
| in % of sales | 21.3% | 21.0% | | 14.2% | 11.8% | |

Consumer and Health Management Information Systems (CHS)

| EUR `000 | 01.10.- 31.12.2019 | 01.10.- 31.12.2018 (adjusted) | Change | 01.01.- 31.12.2019 | 01.01.- 31.12.2018 (adjusted) | Change |
|------------------------------|-----------------------|-------------------------------------|--------|-----------------------|-------------------------------------|--------|
| Sales to third parties | 14.7 | 11.3 | 31% | 45.7 | 38.0 | 20% |
| thereof company acquisitions | 0.7 | 0.2 | | 1.9 | 1.1 | |
| EBITDA | 3.4 | 2.1 | 62% | 11.2 | 5.8 | 95% |
| in % of sales | 23.3% | 18.9% | | 24.6% | 15.2% | |

Other business activities and consolidation

| EUR `000 | 01.10.- 31.12.2019 | 01.10.- 31.12.2018 (adjusted) | Change | 01.01.- 31.12.2019 | 01.01.- 31.12.2018 (adjusted) | Change |
|------------------------|-----------------------|-------------------------------------|--------|-----------------------|-------------------------------------|--------|
| Sales to third parties | -0.0 | -0.8 | | 0.2 | 0.2 | |
| EBITDA | -13.9 | -7.2 | | -44.9 | -23.4 | |

Additional Information

ABOUT COMPUGROUP MEDICAL SE

CompuGroup Medical is one of the leading eHealth companies in the world. With a revenue base of approximately 746 MEUR in 2019, its software products are designed to support all medical and organizational activities in doctors' offices, pharmacies, laboratories and hospitals. Its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. CompuGroup Medical's services are based on a unique customer base of more than 1 million health professionals as users, including doctors, dentists, pharmacists and other service providers in inpatient and outpatient facilities. With locations in 19 countries and products in 56 countries worldwide, CompuGroup Medical is the eHealth company with one of the highest coverage among eHealth service providers. Approximately 5,500 highly qualified employees support customers with innovative solutions for the steadily growing demands of the healthcare system.

FINANCIAL CALENDAR

March 25, 2020 - Annual Report 2019

May 7, 2020 - Interim Report Q1 2020

May 13, 2020 - Annual General Meeting 2020

August 6, 2020 - Interim Report Q2 2020

September 16, 2020 - Capital Markets Day

November 5, 2020 - Interim Report Q3 2020

CONTACT INFORMATION

CompuGroup Medical SE

Investor Relations

Claudia Thomé

Head of Investor Relations

Maria Trost 21

56070 Koblenz

Telephone: +49 (0) 261 8000-7030

Fax: +49 (0) 261 8000-3200

E-Mail: investor@cgm.com

www.cgm.com

CompuGroup Medical SE
Maria Trost 21
56070 Koblenz
Germany

Synchronizing Healthcare



**CompuGroup
Medical**